Eagle Pharmaceuticals (FRA:1E6) Beginning Cash Position : €20.2 Mil (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Beginning Cash Position?

Eagle Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jun. 2023 was €20.2 Mil.

Eagle Pharmaceuticals's quarterly Beginning Cash Position increased from Dec. 2022 (€14.5 Mil) to Mar. 2023 (€51.7 Mil) but then declined from Mar. 2023 (€51.7 Mil) to Jun. 2023 (€20.2 Mil).

Eagle Pharmaceuticals's annual Beginning Cash Position increased from Dec. 2020 (€90.2 Mil) to Dec. 2021 (€91.3 Mil) and increased from Dec. 2021 (€91.3 Mil) to Dec. 2022 (€92.2 Mil).

Eagle Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for Eagle Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Beginning Cash Position Chart

Eagle Pharmaceuticals Annual Data

Trend

Sep13

Sep14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Beginning Cash Position

Get a 7-Day Free Trial

100.78

70.91

90.23

91.29

92.19

Eagle Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Beginning Cash Position	Get a 7-Day Free Trial															65.77	36.93	14.52	51.67	20.21

Eagle Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Eagle Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Eagle Pharmaceuticals (FRA:1E6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (FRA:1E6) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

EGRX:USA

Address

50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677

Website

http://www.eagleus.com

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.

Eagle Pharmaceuticals (FRA:1E6) Headlines

No Headlines